Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Apr;59(4):619-27.
doi: 10.1007/s00262-009-0814-4. Epub 2010 Jan 6.

Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

Affiliations
Comparative Study

Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

A Mander et al. Cancer Immunol Immunother. 2010 Apr.

Abstract

The Cancer Immunotherapy Immunoguiding Program has conducted an IFN-gamma ELISPOT proficiency panel to examine the influence of serum supplementation of test media on assay performance. Sixteen European laboratories analyzed the same PBMC samples using different locally established protocols. Participants generated two simultaneous data sets-one using medium supplemented with serum and one without serum. Performances of the two test conditions were compared by quantifying: (1) the number of viable cells, (2) background spot formation induced in the medium only control and (3) the ability to detect antigen-specific T cell responses. The study demonstrated that the number of viable cells recovered and the overall background spot production were not significantly different between the two conditions. Furthermore, overall laboratory performance was equivalent for the two test conditions; 11 out of 16 laboratories reported equal or greater detection rates using serum-free medium, while 5 laboratories reported decreased detections rates under serum-free conditions. These results show that good performance of the IFN-gamma ELISPOT assay can be achieved under serum-free conditions. Optimization of the protocol for serum-free conditions should result in excellent detection rates and eliminate the requirement of serum batch and stability testing, allowing further harmonization of the assay.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall results from sixteen IFNγ-ELISPOT protocols using serum-supplemented and serum-free media. a Recovery of viable PBMC using trypan blue and a manual haemocytometer, following resting for 2–20 h. b Background spot production (spots per 100,000 PBMC) in the cells plus medium only control. c Detection rates, shown as % of responses detected among the seven possible donor–antigen combinations. The mean values for all samples (D1–D5) and all labs (n = 16) were used to plot minimum and maximum value, the range (error bars), inter-quartile range (boxes), median (horizontal line) and mean (black triangle) for the whole group under serum supplemented or serum-free conditions
Fig. 2
Fig. 2
Inverse correlation between background and detection rates. Mean detection rates for each lab expressed, as the % positive responses as defined in “Materials and methods”, are plotted against the mean cells plus medium only background (spots per 100,000 PBMC) using serum supplemented (open triangles) and serum-free (filled circles) media. Under both conditions, detection rate decreases as background increases. Correlation co-efficients: serum, −0.66; serum-free, −0.72

Similar articles

Cited by

References

    1. van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines. 2008;7:1–5. doi: 10.1586/14760584.7.1.1. - DOI - PubMed
    1. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 1997;30:1–15. doi: 10.1097/01.cji.0000211341.88835.ae. - DOI - PubMed
    1. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Hakansson L. Improving the efficacy of cancer immunotherapy. Eur J Cancer. 2009;45:1424–1431. doi: 10.1016/j.ejca.2008.12.017. - DOI - PubMed
    1. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother. 2007;57:285–288. doi: 10.1007/s00262-007-0379-z. - DOI - PMC - PubMed
    1. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’souza MP. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68–81. doi: 10.1089/aid.2005.21.68. - DOI - PubMed

Publication types

MeSH terms